CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pembrolizumab (Keytruda) for Mismatch Repair Deficient Colorectal Cancer - Details

Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Gastrointestinal
Indication Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.
Review Status Not Filed
Manufacturer Merck Canada Inc.
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.
Last Updated February 25, 2020